EGFR and neoplasm: Our omics analysis of clinical data from cohorts of NSCLC revealed that dysregulation of EGFR/MAP2K1/MTOR/YAP1 signaling pathways are associated with disease progression, anticancer drug resistance, tumor immune infiltration, immune-invasive phenotypes and worse prognosis of the cohorts.